High Body Mass Index in Elderly Patients with DLBCL Treated with Rituximab-Containing Therapy Compensates for Negative Impact of Male Sex

Zheng Zhou, Alfred W Rademaker, Leo I Gordon, Ann S. LaCasce, Allison Crosby-Thompson, Ann Vanderplas, Gregory A. Abel, Maria A. Rodriguez, Auayporn Nademanee, Mark S. Kaminski, Myron S. Czuczman, Michael M. Millenson, Andrew D. Zelenetz, Joyce Niland, Jonathan W. Friedberg, Jane Norma Winter*

*Corresponding author for this work

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Background: The impact of patient body habitus and sex on outcomes in diffuse large B-cell lymphoma (DLBCL) remains controversial. We investigated the impact of body mass index (BMI), body surface area (BSA), age, and sex on clinical outcomes in patients with DLBCL treated in the rituximab era. Patients and Methods: Patients with de novo DLBCL (n=1,386) diagnosed between June 2000 and December 2010 treated with rituximab-containing chemotherapy were identified from the NCCN Oncology Outcomes Database for Non-Hodgkin's Lymphoma. Progression-free survival (PFS) and overall survival (OS) at 3 years were analyzed based on sex, age, and baseline BMI/BSA. Results: High BMI was associated with a lower risk of disease progression or death than low or normal BMI, whereas male sex was associated with poor clinical outcomes, especially among elderly patients (age >60 years). Compared with elderly women, elderly men experienced worse PFS (3-year hazard ratio [HR], 1.5) and OS (3-year HR, 1.6), but these differences diminished with increases in BMI and BSA. In multivariable analysis, normal BMI compared with high BMI was independently associated with poor outcomes (3-year PFS HR, 1.5; OS HR, 1.6) after adjusting for sex. Notably, only 13% of elderly men had BMI less than 25 kg/m2 and only 26% had BSA less than 2 m2. Conclusions: Analysis of unselected patients with DLBCL treated with rituximab-containing chemotherapy confirmed an age-dependent disadvantage to male sex in treatment outcomes, but this effect is abrogated by higher levels of BMI and BSA in most North American men.

Original languageEnglish (US)
Pages (from-to)1274-1281
Number of pages8
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume14
Issue number10
DOIs
StatePublished - Oct 1 2016

    Fingerprint

ASJC Scopus subject areas

  • Oncology

Cite this

Zhou, Z., Rademaker, A. W., Gordon, L. I., LaCasce, A. S., Crosby-Thompson, A., Vanderplas, A., Abel, G. A., Rodriguez, M. A., Nademanee, A., Kaminski, M. S., Czuczman, M. S., Millenson, M. M., Zelenetz, A. D., Niland, J., Friedberg, J. W., & Winter, J. N. (2016). High Body Mass Index in Elderly Patients with DLBCL Treated with Rituximab-Containing Therapy Compensates for Negative Impact of Male Sex. JNCCN Journal of the National Comprehensive Cancer Network, 14(10), 1274-1281. https://doi.org/10.6004/jnccn.2016.0136